Naznin Khan
Family Medicine · Jamaica, NYNPI 1891926853
Payments from drug & device makers
Across 117 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$477
- Exact Sciences$416
- Merck$351
- Novo Nordisk$317
- Amgen$257
- Lilly USA, LLC$184
- plus $840 from 12 others
What the payments were for
- Food & beverage$2,75797%
- Education$863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 18 | $477 |
| Exact Sciences | 16 | $416 |
| Merck | 18 | $351 |
| Novo Nordisk | 14 | $317 |
| Amgen | 9 | $257 |
| Lilly USA, LLC | 8 | $184 |
| Renalytix AI, Inc. | 8 | $158 |
| Boehringer Ingelheim | 2 | $153 |
| Pfizer | 6 | $138 |
| AstraZeneca | 4 | $75 |
| Dexcom, Inc. | 1 | $73 |
| Kowa Pharmaceuticals America, Inc. | 3 | $54 |
| Global Blood Therapeutics, Inc. | 2 | $49 |
| Sanofi Pasteur Inc. | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Phadia US Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,843 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanumetSitagliptin Phos/Metformin Hcl | 121 | $108,722 |
| JardianceEmpagliflozin | 105 | $88,735 |
| OzempicSemaglutide | 82 | $83,436 |
| FarxigaDapagliflozin Propanediol | 87 | $71,144 |
| JanuviaSitagliptin Phosphate | 68 | $50,836 |
| EliquisApixaban | 28 | $23,396 |
| MounjaroTirzepatide | 20 | $20,836 |
| LinzessLinaclotide | 20 | $17,346 |
| TradjentaLinagliptin | 12 | $12,966 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $9,315 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,001 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $6,905 |
| BrilintaTicagrelor | 13 | $5,601 |
| Novolog FlexpenInsulin Aspart | 43 | $5,519 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $5,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia, Janumet Xr | $351 | $166,463200 claims |
| Boehringer IngelheimJardiance, Tradjenta | $153 | $101,702117 claims |
| Novo NordiskOzempic | $317 | $83,43682 claims |
| AstraZenecaFarxiga, Brilinta | $75 | $76,745100 claims |
| PfizerEliquis | $138 | $23,39628 claims |
| Lilly USA, LLCMounjaro | $184 | $20,83620 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $477 | $12,14025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Jamaica
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.